Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
In the extended Phase I trial temozolomide only occasionally exhibited the unpredictable myelosuppression seen with mitozolmide, which is easy to use clinically and generally well tolerated.
Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer
The pharmacokinetic profile of SP1049C showed a slower clearance than has been reported for conventional doxorubicin, and evidence of antitumour activity was seen in some patients with advanced resistant solid tumours.
Phase I trial of temozolomide using an extended continuous oral schedule.
Toxicity was greatest in higher dose cohorts, with a resultant maximum tolerated dose of 85 mg/m2/day, whereas lower dose cohorts tolerated the schedule well, and the area under the temozolomide plasma versus time curve was noncumulative between the first and last week of the schedule.
Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours.
Temozolomide was well tolerated with little subjective toxicity and usually predictable myelosuppression and is a promising new drug in the treatment of primary brain tumours.
Phase I trial of elactocin.
This phase I trial of elactocin identified the dose-limiting toxicity as profound anorexia and malaise and it is recommended that further trials of elACTocin are performed.
Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma
The observation of objective responses and tolerable side effects in this heterogeneous population of patients supports the further investigation of this agent in high-grade gliomas.
Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer.
- D. Boote, I. Dennis, +6 authors N. Bleehen
- MedicineJournal of clinical oncology : official journal…
- 1 February 1996
PSC 833 can be administered in combination with etoposide with acceptable toxicity and an insignificant increase in alpha half-life and significant increase in beta half- life of 19% and 77%, respectively.
The Charing Cross Hospital experience with temozolomide in patients with gliomas.
In conclusion, temozolomide given in this schedule has activity against high grade glioma, however, studies evaluating chemotherapy in primary brain tumours should include a quality-of-life/performance status evaluation in addition to CT or MRI scanning assessment.
Effect of temozolomide on central nervous system relapse in patients with advanced melanoma
The investigation of temozolomide as a replacement for DTIC in systemic treatment regimens for melanoma is supported, with a statistically significant difference in favour of the new agent (P = 0.03).
A phase I study of nolatrexed dihydrochloride in children with advanced cancer. A United Kingdom Children's Cancer Study Group Investigation
Nolatrexed can be safely administered to children with cancer, and there is evidence of therapeutic activity as well as antiproliferative toxicity.